Limits...
Carcinosarcoma of the ovary.

Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC - Br. J. Cancer (2003)

Bottom Line: Twenty-seven of the 40 patients had bulk residual disease present after surgery and this was associated with a worse prognosis (P=0.045).Of the 19 patients who had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months.The overall censored median survival was 8.7 months after a median follow-up of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. maggieharris@chorlton60.freeserve.co.uk

ABSTRACT
We report our experience in the management of patients with carcinosarcoma of the ovary, a rare but aggressive variant of ovarian cancer. Forty patients were treated at a single centre, which is the largest reported series. The median age at diagnosis was 65 years (range 45-86) and the median Karnofsky performance (KP) status was 70. Thirty-two patients (80%) presented with FIGO stage III or IV disease. Twenty-four had heterologous and 14 homologous carcinosarcoma on review of histopathology, but there was no significant difference in survival between these groups (P=0.28). Twenty-seven of the 40 patients had bulk residual disease present after surgery and this was associated with a worse prognosis (P=0.045). Chemotherapy was given to 32 patients (80%) of whom 26 (81%) received platinum-based regimens. Of these 32 patients, three (9.4%) achieved a complete response (CR), 10 (31%) a partial response (PR), five (16%) had stable disease, 10 (31%) had progressive disease and four were not assessable. Of the 19 patients who had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months. Currently, seven patients are still alive although one has cancer. The overall censored median survival was 8.7 months after a median follow-up of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively.

Show MeSH

Related in: MedlinePlus

Relation between stage and survival. Survival was classified according to stages 1/2 and 3/4. The number of patients at risk are shown below the x-axis. The dotted line represents patients with stage 1 or 2 disease. The solid line represents patients with stages 3 and 4 disease. The stage in one patient could not be determined.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376340&req=5

fig2: Relation between stage and survival. Survival was classified according to stages 1/2 and 3/4. The number of patients at risk are shown below the x-axis. The dotted line represents patients with stage 1 or 2 disease. The solid line represents patients with stages 3 and 4 disease. The stage in one patient could not be determined.

Mentions: Currently seven patients are still alive, one with cancer, and there have been two intercurrent deaths. The other 31 patients have died of their disease. The overall censored median survival was 8.7 months and the median follow-up period from diagnosis was 34 months. The stage-related survival curves are shown in Figure 2Figure 2


Carcinosarcoma of the ovary.

Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC - Br. J. Cancer (2003)

Relation between stage and survival. Survival was classified according to stages 1/2 and 3/4. The number of patients at risk are shown below the x-axis. The dotted line represents patients with stage 1 or 2 disease. The solid line represents patients with stages 3 and 4 disease. The stage in one patient could not be determined.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376340&req=5

fig2: Relation between stage and survival. Survival was classified according to stages 1/2 and 3/4. The number of patients at risk are shown below the x-axis. The dotted line represents patients with stage 1 or 2 disease. The solid line represents patients with stages 3 and 4 disease. The stage in one patient could not be determined.
Mentions: Currently seven patients are still alive, one with cancer, and there have been two intercurrent deaths. The other 31 patients have died of their disease. The overall censored median survival was 8.7 months and the median follow-up period from diagnosis was 34 months. The stage-related survival curves are shown in Figure 2Figure 2

Bottom Line: Twenty-seven of the 40 patients had bulk residual disease present after surgery and this was associated with a worse prognosis (P=0.045).Of the 19 patients who had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months.The overall censored median survival was 8.7 months after a median follow-up of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. maggieharris@chorlton60.freeserve.co.uk

ABSTRACT
We report our experience in the management of patients with carcinosarcoma of the ovary, a rare but aggressive variant of ovarian cancer. Forty patients were treated at a single centre, which is the largest reported series. The median age at diagnosis was 65 years (range 45-86) and the median Karnofsky performance (KP) status was 70. Thirty-two patients (80%) presented with FIGO stage III or IV disease. Twenty-four had heterologous and 14 homologous carcinosarcoma on review of histopathology, but there was no significant difference in survival between these groups (P=0.28). Twenty-seven of the 40 patients had bulk residual disease present after surgery and this was associated with a worse prognosis (P=0.045). Chemotherapy was given to 32 patients (80%) of whom 26 (81%) received platinum-based regimens. Of these 32 patients, three (9.4%) achieved a complete response (CR), 10 (31%) a partial response (PR), five (16%) had stable disease, 10 (31%) had progressive disease and four were not assessable. Of the 19 patients who had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months. Currently, seven patients are still alive although one has cancer. The overall censored median survival was 8.7 months after a median follow-up of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively.

Show MeSH
Related in: MedlinePlus